Examination of First and Second Generation E-cigarettes

第一代和第二代电子烟的检验

• 批准号: 10015208
• 负责人: Theodore Lee Wagener
• 金额: $ 53.82万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10015208
• 关键词: Adult; Biological Markers; Cigarette; DNA Damage; Data; Devices; Electronic cigarette; Enrollment; Evolution; Exposure to; Family Smoking Prevention and Tobacco Control Act; Foundations; Generations; Grant; Health; Heating; Investigation; Knowledge; Lead; Literature; Marketing; Measures; Nicotine; Nicotine Dependence; Outcome; Participant; Pattern; Physiological; Proliferating; Prospective Studies; Public Health; Randomized; Regulation; Research; Science; Smoke; Smoker; Smoking; Smoking Behavior; Smoking and Health Research; Stratification; Tobacco; Tobacco Industry; Toxicant exposure; Work; authority; base; cancer risk; carcinogenicity; cigarette smoke; cigarette smoking; cost; design; electronic cigarette use; electronic cigarette user; innovation; novel; prospective; public health relevance; tobacco products; toxicant; vapor

 DESCRIPTION (provided by applicant): The 2009 Family Smoking Prevention and Tobacco Control Act grants the FDA regulatory authority over tobacco-based products. However, the FDA only recently proposed deeming regulations on e-cigarettes. Since their market emergence, e-cigarettes have evolved from first generation products, which look like a conventional cigarette, have few design components and limited nicotine delivery, to second generation products, which do not look like conventional cigarettes, have multiple design components and can achieve cigarette-like levels of nicotine-delivery. Missing from the current literature is a prospective study assessing differences between these two major types of e-cigarettes on smoking behaviors and patterns, nicotine dependence, and on biomarkers of toxicant exposure and effect. Understanding the differential impact of first versus second generation e-cigarettes on smoking as well as measures of proximal health outcomes will help immediately inform the science base needed for the FDA to impose appropriate product specific regulations. The overall aim of the proposed study is to evaluate the effect of switching from conventional cigarettes to either a first or second generation e-cigarette on smoking behavior, product use patterns and continued use, as well as biomarkers of toxicant exposure and effects. To do so, we will randomly assign 453 adult smokers, naïve to e-cigarette use, to first generation e-cigarette (G1), second generation e-cigarette (G2), or usual brand cigarette control (UBC). All products will be provided for 12 weeks. Enrollment will be restricted only to smokers not planning to quit in the next 3 months. Prior to randomization, all participants will take part n a lead-in period to assess normal smoking behavior and to allow for stratification on important variables. Follow- ups will occur at 1, 4, 8, 12, 26, and 52 weeks. Our specific aims are to 1) assess the effect of provision of G1 vs. G2 on product switching, abuse liability, number of cigarettes smoked, and perceived nicotine dependence; 2) evaluate changes in biomarkers of harmful tobacco constituent exposure among participants assigned to G1, G2, and UBC; and 3) evaluate changes in biomarkers of toxicant effect among participants assigned to G1, G2, and UBC. This innovative study in its comprehensive examination of all e-cigarette devices as well as their impact on smoking behavior and health outcomes, will provide the scientific foundation the FDA and other agencies need to establish effective regulatory strategies for the manufacture, distribution, and marketing of e- cigarettes.

 描述（由申请人提供）：2009 年《家庭吸烟预防和烟草控制法案》授予 FDA 对烟草产品的监管权。然而，自电子烟市场出现以来，FDA 直到最近才提出了有关电子烟的监管规定。从第一代产品（看起来像传统卷烟，设计成分很少，尼古丁释放量有限）发展到第二代产品，第二代产品看起来不像传统卷烟，有多种设计成分，并且可以实现目前的文献中缺少一项前瞻性研究，该研究评估了这两种主要类型的电子烟在吸烟行为和模式、尼古丁依赖性以及有毒物质暴露和影响的生物标志物方面的差异。第一代电子烟与第二代电子烟对吸烟的影响以及近期健康结果的衡量标准将有助于立即为 FDA 实施适当的产品特定法规提供所需的科学依据。拟议研究的总体目标是评估电子烟的影响。从传统的转换为了做到这一点，我们将随机分配 453 名从未使用过电子烟的成年吸烟者。 、第一代电子烟（G1）、第二代电子烟（G2）或普通品牌香烟控制（UBC）。所有产品将仅限于不打算戒烟的吸烟者提供。在接下来的 3 个月内，在随机分组之前，所有参与者都将参加导入期，以评估正常吸烟行为，并在 1、4、8、12、26 日进行随访。我们的具体目标是 1) 评估提供 G1 与 G2 对产品转换、滥用倾向、吸烟数量和感知尼古丁依赖的影响 2) 评估分配给 G1、G2 和 UBC 的参与者中有害烟草成分暴露的生物标志物；3) 评估分配给 G1、G2 和 UBC 的参与者中有毒效应的生物标志物的变化。这项创新研究对所有电子烟进行了全面检查。设备及其对吸烟行为和健康结果的影响，将为 FDA 和其他机构为电子烟的制造、分销和营销制定有效的监管策略提供所需的科学基础。